178 related articles for article (PubMed ID: 37562108)
21. Evaluation of Axillary Lymph Node Marking with Magseed® before and after Neoadjuvant Systemic Therapy in Breast Cancer Patients: MAGNET Study.
Martínez M; Jiménez S; Guzmán F; Fernández M; Arizaga E; Sanz C
Breast J; 2022; 2022():6111907. PubMed ID: 35855102
[TBL] [Abstract][Full Text] [Related]
22. Comparing Early-Stage Breast Cancer Patients with Sentinel Lymph Node Metastasis with and without Completion Axillary Lymph Node Dissection: A Systematic Review and Meta-Analysis.
Heiranizadeh N; Rafiei Shahamabadi M; Dehghan HR; Jafari-Nedooshan J; Kargar S; Zare M; Amooei A; Shiryazdi SM; Broomand MA; Moravej MT; Sadri Z
Asian Pac J Cancer Prev; 2022 Aug; 23(8):2561-2571. PubMed ID: 36037108
[TBL] [Abstract][Full Text] [Related]
23. Is repeat sentinel lymph node biopsy possible for surgical axillary staging among patients with ipsilateral breast tumor recurrence?
Lu X; He M; Yu L; Gou Z
Cancer; 2023 May; 129(10):1492-1501. PubMed ID: 36807239
[TBL] [Abstract][Full Text] [Related]
24. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
Damin AP; Zancan M; Melo MP; Biazus JV
Breast Cancer Res Treat; 2021 Apr; 186(2):527-534. PubMed ID: 33165710
[TBL] [Abstract][Full Text] [Related]
25. Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer.
Simons JM; van Pelt MLMA; Marinelli AWKS; Straver ME; Zeillemaker AM; Pereira Arias-Bouda LM; van Nijnatten TJA; Koppert LB; Hunt KK; Smidt ML; Luiten EJT; van der Pol CC
Br J Surg; 2019 Nov; 106(12):1632-1639. PubMed ID: 31593294
[TBL] [Abstract][Full Text] [Related]
26. Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient.
Franceschini G; Di Leone A; Sanchez AM; D'Archi S; Terribile D; Magno S; Scardina L; Masetti R
Ann Ital Chir; 2020; 91():465-468. PubMed ID: 32312945
[TBL] [Abstract][Full Text] [Related]
27. Arm morbidity of axillary dissection with sentinel node biopsy versus delayed axillary dissection.
Ballal H; Hunt C; Bharat C; Murray K; Kamyab R; Saunders C
ANZ J Surg; 2018 Sep; 88(9):917-921. PubMed ID: 29392828
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: a systematic review and meta-analysis.
Fan YJ; Li JC; Zhu DM; Zhu HL; Zhao Y; Zhu XB; Wu G; Bai TT
BMC Surg; 2023 Jul; 23(1):209. PubMed ID: 37495945
[TBL] [Abstract][Full Text] [Related]
29. Axillary treatment for operable primary breast cancer.
Bromham N; Schmidt-Hansen M; Astin M; Hasler E; Reed MW
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004561. PubMed ID: 28052186
[TBL] [Abstract][Full Text] [Related]
30. Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer.
Kuemmel S; Heil J; Bruzas S; Breit E; Schindowski D; Harrach H; Chiari O; Hellerhoff K; Bensmann E; Hanf V; Graßhoff ST; Deuschle P; Belke K; Polata S; Paepke S; Warm M; Meiler J; Schindlbeck C; Ruhwedel W; Beckmann U; Groh U; Dall P; Blohmer JU; Traut A; Reinisch M
JAMA Surg; 2023 Aug; 158(8):807-815. PubMed ID: 37285140
[TBL] [Abstract][Full Text] [Related]
31. Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2021 Sep; 38():101636. PubMed ID: 34303211
[TBL] [Abstract][Full Text] [Related]
32. Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype.
Di Micco R; Zuber V; Fiacco E; Carriero F; Gattuso MI; Nazzaro L; Panizza P; Gianolli L; Canevari C; Di Muzio N; Pasetti M; Sassi I; Zambetti M; Gentilini OD
Eur J Surg Oncol; 2019 Jun; 45(6):969-975. PubMed ID: 30744944
[TBL] [Abstract][Full Text] [Related]
33. Partial axillary lymph node dissection inferior to the intercostobrachial nerves complements sentinel node biopsy in patients with clinically node-negative breast cancer.
Li J; Jia S; Zhang W; Qiu F; Zhang Y; Gu X; Xue J
BMC Surg; 2015 Jun; 15():79. PubMed ID: 26123412
[TBL] [Abstract][Full Text] [Related]
34. Using the axillary reverse mapping technique to screen breast cancer patients with a high risk of lymphedema.
Liu S; Wang N; Gao P; Liu P; Yang H; Xie F; Wang S; Liu M; Wang S
World J Surg Oncol; 2020 Jun; 18(1):118. PubMed ID: 32482174
[TBL] [Abstract][Full Text] [Related]
35. The evolution of the sentinel node procedure in the treatment of breast cancer.
Tvedskov TF
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975889
[TBL] [Abstract][Full Text] [Related]
36. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer.
Andreis D; Bonardi S; Allevi G; Aguggini S; Gussago F; Milani M; Strina C; Spada D; Ferrero G; Ungari M; Rocca A; Nanni O; Roviello G; Berruti A; Harris AL; Fox SB; Roviello F; Polom K; Bottini A; Generali D
Breast; 2016 Oct; 29():55-61. PubMed ID: 27428471
[TBL] [Abstract][Full Text] [Related]
37. Factors Predictive of Sentinel Lymph Node Involvement in Primary Breast Cancer.
Malter W; Hellmich M; Badian M; Kirn V; Mallmann P; Krämer S
Anticancer Res; 2018 Jun; 38(6):3657-3662. PubMed ID: 29848724
[TBL] [Abstract][Full Text] [Related]
38. False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy.
de Boniface J; Frisell J; Kühn T; Wiklander-Bråkenhielm I; Dembrower K; Nyman P; Zouzos A; Gerber B; Reimer T; Hartmann S
Breast Cancer Res Treat; 2022 Jun; 193(3):589-595. PubMed ID: 35451733
[TBL] [Abstract][Full Text] [Related]
39. Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy.
Tasdoven I; Balbaloglu H; Erdemir RU; Bahadir B; Guldeniz Karadeniz C
Medicine (Baltimore); 2022 Dec; 101(52):e32545. PubMed ID: 36596061
[TBL] [Abstract][Full Text] [Related]
40. Impact of Axillary Lymph Node Dissection and Sentinel Lymph Node Biopsy on Upper Limb Morbidity in Breast Cancer Patients: A Systematic Review and Meta-Analysis.
Che Bakri NA; Kwasnicki RM; Khan N; Ghandour O; Lee A; Grant Y; Dawidziuk A; Darzi A; Ashrafian H; Leff DR
Ann Surg; 2023 Apr; 277(4):572-580. PubMed ID: 35946806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
